Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has 5 years of Amortization of Deferred Charges data on file, last reported at $64000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 56.46% year-over-year to $64000.0 in Q1 2026; TTM through Mar 2026 was $132000.0, a 82.33% decrease from a year earlier, with the FY2025 full-year figure at $215000.0, down 67.13% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $64000.0, up from -$235000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for OBIO reached as high as $444000.0 in Q4 2022 and fell as low as -$361000.0 in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $95058.8 across 5 years, with a median of $149000.0 in 2024.
• Across the five-year window, Amortization of Deferred Charges surged 212.68% in 2023 and slumped 257.72% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $444000.0 in 2022, then plunged by 181.31% to -$361000.0 in 2023, then soared by 141.27% to $149000.0 in 2024, then slumped by 257.72% to -$235000.0 in 2025, then surged by 127.23% to $64000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $64000.0 in Q1 2026, -$235000.0 in Q4 2025, and $153000.0 in Q3 2025.